Immucor acquisitions under FTC (Federal Trade Commission) investigation
This article was originally published in Clinica
Blood screening specialist Immucor has come under the scrutiny of the US Federal Trade Commission (FTC) in a non-public investigation over a possible breach of federal antitrust laws. The FTC sent Immucor a letter, received on October 12, requesting certain documents and information connected to three acquisitions made from 1996 to 1999.
You may also be interested in...
Diagnostics company Bodysphere had to retract an announcement that it had received an emergency use authorization from the US FDA for a COVID-19 serologic test. See why Bethany Hills, an attorney with law firm Morrison & Foerster, says this may be a cautionary tale for other manufacturers.
Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.
Japanese ICT giant applies novel advanced computing techniques with a US venture partner to more rapidly identify lead molecules from a huge virtual space.